A B S TRA CT In order to determine whether an adrenergic mechanism is involved in the secretion of growth hormone and insulin, the effect of adrenergic-blocking or -stimulating agents on plasma human growth hormone (HGH), immunoreactive insulin, blood free fatty acids (FFA), and glucose levels was studied in normal human subjects.
A B S TRA CT In order to determine whether an adrenergic mechanism is involved in the secretion of growth hormone and insulin, the effect of adrenergic-blocking or -stimulating agents on plasma human growth hormone (HGH), immunoreactive insulin, blood free fatty acids (FFA), and glucose levels was studied in normal human subjects.
The intravenous infusion of propranolol, a beta adrenergic-blocking agent, caused a rise in plasma HGH, a transient decrease in blood FFA, and no significant change in plasma insulin. This increase in plasma HGH was inhibited either by the combined administration of isoproterenol, a beta adrenergic-stimulating agent, along with propranolol or by oral glucose loading immediately before the start of propranolol infusion. The concomitant administration of epinephrine and propranolol brought about a rise in plasma HGH comparable with that produced by propranolol alone, without any significant change in blood FFA. Alpha adrenergic blockade by the intravenous infusion of phenotolamine significantly suppressed plasma HGH responses to insulin-induced hypoglycemia and to arginine infusion, and enhanced plasma insulin response to arginine infusion. It also stimulated lipid mobilization significantly.
The intravenous infusion of alpha adrenergic-stimulating agents, phenylephrine and methoxamine, caused an increase in plasma HGH, a slight decrease in blood FFA, and no significant change in plasma insulin. This increase in plasma HGH was significantly inhibited by the simultaneous administration of phentolamine along
INTRODUCTION
It has been clarified in recent years that secretion of human growth hormone (HGH)1 is influenced by several factors, such as rapid changes in blood glucose level, amino acid ingestion, exercise, and stress (1) (2) (3) . These stimuli appear to act through the hypothalamus, although the exact mechanism is still unknown. Several investigators (4) (5) (6) have demonstrated evidence for the presence of growth hormone-releasing factor (GRF), which is produced in the hypothalamus, transported to the anterior pituitary via the portal vessels, and stimulates HGH secretion. However, the chemical structure and the mechanism of secretion of GRF remain obscure.
induced hypoglycemia and the lack of a normal response to oral glucose administration (7) . These abnormalities suggest that catecholamines may play a role in regulating HGH secretion. Although it has been reported that the injection of catecholamines did not influence plasma HGH levels in man (1, 8, 9) , we thought it interesting to study further the role of the adrenergic mechanisms in regulating HGH secretion.
These studies are also interesting in another aspect. Porte, Graber, Kuzuya, and Williams (10) and Porte (11) have reported that the adrenergic mechanism is involved in insulin secretion and that beta adrenergic receptor blockade suppresses insulin secretion, whereas alpha blockade stimulates it. Since there are close relationships between insulin and HGH secretion, it seemed worthwhile to compare the adrenergic receptor mechanisms for the secretion of these two hormones.
In the present experiments, the effect of adrenergicblocking or -stimulating agents on plasma HGH and IRI levels were studied in normal subjects. It was demonstrated that either beta adrenergic blockade or alpha stimulation enhanced HGH secretion and suppressed insulin secretion, whereas either alpha blockade or beta stimulation enhanced insulin secretion and suppressed HGH secretion.
METHODS
Male and female volunteers, aged 1942, were used throughout the experiments. None of them had a family history of diabetes nor elevated fasting blood sugar level. They were nonobese (less than 15% above ideal body weight) and apparently normal in endocrine and autonomic nervous function. Some subjects were used for several experiments with an interval of at least 1 wk between the two experiments, whereas others were used for only one experiment.
The subjects were not allowed to smoke or to take anything by mouth except water after 10 p.m. the night before the study. They came to the laboratory at 8:00-8:30 a.m. and then lay still throughout the experiment. Two control blood specimens were withdrawn between 9:00 and 9:30 a.m., and a slow intravenous infusion of 500 ml of physiologic saline containing adrenergic-blocking or -stimulating agents was given at a constant rate over a period of (12) . In this modified method, hydroxylamine hydrochloride, acetic acid, and batho-cuproine2 were used instead of sodium diethyldithiocarbamate to develop the color of the copper salts of fatty acids extracted in chloroform because this modification gives better reproducibility. Plasma IRI was measured by the immunoassay kit of the Radiochemical Centre (Amersham, England) which is based upon the double antibody immunoprecipitation technique (method C) of Hales and Randle (13) . The minimal detectable quantity of IRI for the assay was 5 AU/ml. Repeated determinations of two pooled plasmas on 10 different days gave coefficients of variance of 8.8% and 10.1%, for the two pools.
Plasma HGH was measured by the double antibody radioimmunoassay of Schalch and Parker (14) . Anti-HGH serum was prepared in a guinea pig by several weekly injections of 1 mg of HGH (Li) emulsified in 0.5 ml of complete Freund's adjuvant. This antiserum showed one precipitation arc with HGH, but not with human serum when tested by immunoelectrophoresis. Anti-guinea pig 'y-globulin serum was obtained from rabbits which received repeated injections of guinea pig y-globulin in complete Freund's adjuvant. HGH (Wilhelmi, HS705A) was labeled with "31I by the method of Greenwood, Hunter, and Glover (15) . Specific activities of 150450 /ACi/jug were obtained. All standards (Wilhelmi's HGH) and plasma samples were assayed in duplicate. The minimal detectable value of HGH for the assay was 0.1 mwug/ml. In plasma assays at various levels, the range of difference between duplicates as millimicrograms per milliliter was usually less than 10%.
In order to determine the effect of beta adrenergic blockade, intravenous infusions of 10 mg of propranolol were given to 14 subjects (7 males and 7 females). Concomitant administration of 10 mg of propranolol with 0.36 mg of isoproterenol or with 0.72 mg of epinephrine was performed in four and five subjects, respectively. In five subjects, 50 g of glucose was given orally immediately before the start of propranolol infusion, to determine whether glucose administration influences the HGH response to propranolol.
In the second series of experiments, the effect of an alpha adrenergic-blocking agent on plasma HGH and IRI was studied. Either 10 mg or 20 mg of phentolamine dissolved in 500 ml of saline was infused in six normal subjects. In another six subjects, intravenous infusions of 20 mg of phentolamine in 500 ml saline and 30 g of 1-arginine in 500 ml solution were started at the same time in both antecubital veins and continued for 2 hr and 30 min, respectively. 1 wk later, 500 ml of physiologic saline and 1-arginine solution were infused in the same normal subjects as a control experiment. In another three subjects, 20 mg of phentolamine was infused over a period of 2 hr. Immediately after the start of infusion, glucagon-free insulin (0.1 U/kg body weight) was injected intravenously. After 1 wk, insulin was given during the infusion of 60 mg of phentolamine in the same subjects, and 1 wk later, insulin was injected during the infusion of physiologic saline as a control experiment. 2 Trivial names used in this paper: propranolol, 1-isopro- Intravenous infusion of an alpha adrenergic-stimulating agent, 1 mg, 3 mg, or 10 mg of phenylephrine, in 500 ml of saline solution was performed over a period of 2 hr in 10 subjects. Another alpha-stimulating agent, 25 mg of methoxamine, was infused in seven subjects. Combined administation of 25 mg of methoxamine and 20 mg of phentolamine in 500 ml of saline was performed in four subjects. Intravenous infusions of two different beta adrenergicstimulating agents, 15 mg or 30 mg of isoxsuprine and 0.36 mg of isoproterenol, were given to six and four subjects, respectively. As a control, 500 ml of physiologic saline was given intravenously over a period of 2 hr in six normal subj ects.
Propranolol (Inderal) was kindly supplied by Sumitomo Chemical Industry Co., Osaka, Japan. Phentolamine (Regitine) was purchased from Ciba Products Co., Osaka, Japan. Phenylephrine (Neo Synesin) and methoxamine (Vasoxyl) were gifts from Kowa Co., Nagoya, Japan, and Burroughs Wellcome Co. Inc., Tuckahen, N. Y., respectively. Isoxsuprine (Duvadilan) was supplied by Dai-ichi Seiyaku Co., Tokyo, Japan. Isoproterenol (Proternol-L) was purchased from Nikken Kagaku Co., Tokyo, Japan. Arginine solution was kindly supplied by Tanabe Pharmaceutical Co., Osaka, Japan.
RESULTS Effect of beta adrenergic-blocking agent on plasma HGH, IRI, blood FFA, and glucose. The concomitant administration of isoproterenol, a beta adrenergic-stimulating agent, with propranolol completely abolished plasma HGH response to propranolol in all subjects tested as shown in Fig. 1 . The plasma IRI response to isoproterenol, described later in this paper, was also completely suppressed by the simultaneous infusion of propranolol. A transient rise in blood FFA was observed, whereas no significant change was noted in blood glucose throughout the experiment.
Combined intravenous infusion of epinephrine with propranolol brought about almost the same rise in plasma HGH as did propranolol alone as shown in Fig.  2 . Peak plasma HGH levels during the combined infusion were from 8.4 to 35.9 mrsg/ml. Blood FFA concentrations did not change significantly until 90 min after the start of the infusion and then declined gradually. Blood glucose rose significantly to a peak 90 min after the start of the infusion. Plasma IRI rose slightly only after the end of the infusion, in spite of the significant increase in blood glucose levels during the infusion.
The IRI caused by phentolamine was also suppressed by the combined administration of methoxamine. Blood FFA rose slightly during the combined administration, whereas it tended to decrease during the infusion of methoxamine alone.
Effect of beta adrencrgic-stinmulating agcnts on plasma HGH, IRI, blood FFA, and glucose. Plasma HGH levels tended to decrease during the infusion of isoxsuprine, a beta adrenergic-stimulating agent, although they _* i~increased slightly in four of six subjects after the end of infusion as shown in Fig. 9 alpha adrenergic-stimulating agent, caused a significant increase in plasma HGH during the infusion in two and after the end of the infusion in three-of seven subjects tested (Table III) . There seemed to be no significant difference in plasma HGH response between three subjects given 1 mg and four subjects given 3 mg of phenylephrine. However, no significant change in plasma HGH was noted in subjects given 10 mg of phenylephrine (Table III) . Blood FFA concentrations were transiently decreased during the infusion of 1 mg of phenylephrine, but increased during the infusion of 10 mg of the drug as shown in Table III . No significant change was observed in blood glucose and plasma IRI in all the subjects tested.
Intravenous infusion of another alpha adrenergicstimulating agent, methoxamine, caused a rise in plasma HGH during the infusion in all subjects tested as shown in Fig. 7 . A transient, slight decline in blood FFA concentrations was observed during the infusion, whereas no significant change was noted in blood glucose.
Plasma HGH response to methoxamine was significantly blunted by the simultaneous administration of phentolamine, an alpha adrenergic-blocking agent, as shown in Fig. 8 The present experiment also demonstrated that phentolamine significantly enhanced the plasma IRI response to arginine infusion. It has been known that epinephrine inhibits plasma IRI responses to glucose, glucagon, and tolbutamide (10) and that phentolamine stimulates IRI release when infused with epinephrine (11) . However, the effect of epinephrine on insulin secretion elicited by amino acids is still controversial (8, 21, 22) , and the effect of adrenergic-blocking agents on amino acidinduced insulin release is unknown. The present experiment strongly suggests that alpha adrenergic blockade enhances the insulin secretion elicited by amino acids.
The effect of adrenergic-stimulating agents on plasma HGH and IRI was less clear-cut than that of adrenergicblocking agents, probably because adrenergic-stimulating agents are usually less specific than blocking agents. For example, phenylephrine is a potent alpha receptor stimulant, but with a little stimulating effect on beta receptors (23) . A small dose of phenylephrine brought about a rise in plasma HGH and a decrease in blood FFA in most of the subjects, although a large dose of the drug failed to increase plasma HGH and even raised blood FFA. These results suggest that alpha stimulation is predominant with a small dose of phenylephrine, whereas beta stimulation becomes apparent after a large dose, although the possibility of chance variation could not (1, 17) . A fall in blood glucose stimulates the secretion of catecholamines, which inhibit insulin secretion and probably assist in enhancing HGH secretion through alpha receptors. Although a single injection of catecholamines fails to affect HGH levels in man, we observed that consistent elevation of plasma catecholamines in pheochromocytoma enhances HGH secretion induced by hypoglycemia and prevents suppression of HGH secretion by glucose administration (7) .
In vitro experiments on the effect of adrenergic agents on fat mobilization from adipose tissue and on insulin secretion from the islets of the pancreas indicate that the adrenergic mechanism may reside in the fat cells or in the islet cells themselves (26, 27) . However, it is still unknown in what process the adrenergic mechanism may be involved in HGH secretion. It might reside anywhere in the hypothalamo-hypophyseal system or even in another portion of the central nervous system. However, the hypothalamus is the most likely site because of its high norepinephrine content as well as abundant adrenergic neurons and because of the fact that norepinephrine depletors block growth hormone release induced by hypoglycemia but not by GRF (28) . It is possible, therefore, that the neurons which detect stimuli such as a fall in blood sugar and stimulate discharges of GRF are adrenergic. However, the possibility of dopaminergic neurons cannot be ruled out completely, since Schneider and McCann (29) reported that dopamine stimulates LH release from the pituitary when incubated with stalk median eminence tissue and that phentolamine inhibits the action of dopamine. It seems reasonable to speculate, therefore, that alpha adrenergic receptors stimulated by norepinephrine, or possibly dopamine, enhance GRF secretion.
